Antitumour activity of Emblica officinalis.
Aqueous extract of Emblica officinalis (E.O) was found to be cytotoxic to L 929 cells in culture in a dose dependent manner. Concentration needed for 50% inhibition was found to be 16.5 microg/ml. E.O and chyavanaprash (a non-toxic herbal preparation containing 50% E.O) extracts were found to reduce ascites and solid tumours in mice induced by DLA cells. Animals treated with 1.25 g/kg b.wt. of E.O extract increased life span of tumour bearing animals (20%) while animals treated with 2.5 g/kg b.wt. of chyavanaprash produced 60.9% increased in the life span. Both E.O and chyavanaprash significantly reduced the solid tumours. Tumour volume of control animals on 30th day was 4.6 ml where as animals treated with 1.25 g/Kg b.wt. of E.O extract and 2.5 g/kg b.wt. of chyavanaprash showed a tumour volume of 1.75 and 0.75 ml, respectively. E.O extract was found to inhibit cell cycle regulating enzymes cdc 25 phosphatase in a dose dependent manner. Concentration needed for 50% inhibition of cdc 25 phosphatase was found to be 5 microg/ml and that needed for inhibition of cdc2 kinase was found to be >100 microg/ml. The results suggest that antitumour activity of E.O extract may partially be due to its interaction with cell cycle regulation.
Jose
J K
JK
Amala Cancer Research Centre, Amala Nagar P.O., 680 553, Kerala, Trissur, India.
Kuttan
G
G
Kuttan
R
R
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000302:isolation & purification / Q000494:pharmacology* / Q000627:therapeutic use; D001201:Ascites / Q000188:drug therapy; D002453:Cell Cycle / Q000187:drug effects; D004354:Drug Screening Assays, Antitumor; D019665:Euphorbiaceae / Q000737:chemistry*; D008297:Male; D051379:Mice; D008517:Phytotherapy; D010936:Plant Extracts / Q000494:pharmacology* / Q000627:therapeutic use; D014407:Tumor Cells, Cultured
D000972:Antineoplastic Agents, Phytogenic; D010936:Plant Extracts